As Introduced

127th General Assembly Regular Session 2007-2008

H. B. No. 39

Representative Skindell

Cosponsors: Representatives Stewart, D., Foley, Koziura, Ujvagi, Strahorn, Lundy, Hagan, R., Bolon, Brady, Beatty

A BILL

То	amend section 3715.99 and to enact sections	1
	3715.88, 3715.89, and 3715.90 of the Revised Code	2
	to require manufacturers and labelers of dangerous	3
	drugs to disclose to the Director of Health the	4
	value, nature, and purpose of certain gifts, fees,	5
	payments, subsidies, and other economic benefits	6
	they provide in connection with pharmaceutical	7
	detailing, marketing, or promotion.	8

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

Section 1. That section 3715.99 be amended and sections	9
3715.88, 3715.89, and 3715.90 of the Revised Code be enacted to	10
read as follows:	11
Sec. 3715.88. (A) As used in this section and section 3715.89	12
of the Revised Code:	13
(1) "Detailing" means the marketing or promotion of dangerous	14
drugs by or on behalf of a manufacturer or labeler.	15
(2) "Labeler" means a person to whom both of the following	16
apply:	17

(a) The person receives dangerous drugs from a manufacturer	18	
or wholesaler and repackages them for retail sale.	19	
(b) The person has a labeler code from the United States food	20	
and drug administration under 21 C.F.R. 207.20.	21	
(3) "Marketer" means a person who, while employed by or under	22	
contract to represent a manufacturer or labeler, engages in	23	
pharmaceutical detailing or other marketing or promotion of	24	
dangerous drugs.	25	
	26	
(4) "Sample drug" has the same meaning as in section 2925.01	27	
of the Revised Code.	۷ /	
(5) "Wholesaler" means a person who, on official written	28	
orders other than prescriptions, supplies dangerous drugs that the	29	
person has not manufactured, produced, or prepared personally and	30	
includes a "wholesale distributor of dangerous drugs" as defined	31	
in section 4729.01 of the Revised Code.	32	
(B) On or before the first day of January of each year, each	33	
manufacturer and labeler that sells dangerous drugs shall disclose		
to the director of health the name and address of the individual	35	
responsible for the manufacturer's or labeler's compliance with	36	
this section.	37	
(C) Subject to division (E) of this section, no manufacturer	38	
or labeler that sells dangerous drugs shall fail, on or before the	39	
first day of February of each year, to disclose to the director	40	
the value, nature, and purpose of any gift, fee, payment, subsidy,	41	
or other economic benefit provided in connection with detailing,	42	
promotion, or other marketing activities by the manufacturer or	43	
labeler, directly or through a marketer, to any licensed health	44	
professional authorized to prescribe drugs, hospital, nursing	45	
home, residential care facility, adult care facility, pharmacist,		
or health plan administrator. Disclosure shall cover the prior	46 47	
calendar year and be made on a form and in a manner prescribed by	48	

(B) Define the terms "bona fide clinical trial" and "bona

fide educational, scientific, or policy-making conference for

77

78

H. B. No. 39 As Introduced	Page 5
Section 2. That existing section 3715.99 of the Revised Code	109
is hereby repealed.	110